Profile data is unavailable for this security.
About the company
Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. Its segments include Bulk Drugs and Formulations. It is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. Its APIs include ascorbic acid, CH Base and its derivatives, citicoline sodium, carbamazepine, theobromine, ferrous ascorbate, doxofylline, oxcarbazepine, choline bitartrate and its derivatives, octenidine dihydrochloride, vildagliptin, ticagrelor, diosmin, hesperidin and others. Its FDFs include Cellin 500, Septran DS Tablet, Vitajaj C tables 500mg, Ticajaj 90 tablets, Ecojaj 75mg & 150mg, Deferajaj 400mg & 500mg, Vildajaj 50mg and Vildajaj M 50/500. It also offers Inositol Nicotinate and Magnesium L-Threonate.
- Revenue in INR (TTM)4.98bn
- Net income in INR212.66m
- Incorporated1993
- Employees1.06k
- LocationBajaj Healthcare Ltd202-204Faiz-E-Qutbi, 375,Narshi Natha StreetTHANE 400604IndiaIND
- Phone+91 2 240177400
- Fax+91 2 266177458
- Websitehttp://www.bajajhealth.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kilitch Drugs (India) Ltd | 1.55bn | 145.71m | 5.70bn | 153.00 | 38.49 | -- | 35.36 | 3.68 | 9.21 | 9.21 | 98.24 | -- | -- | -- | -- | 10,132,730.00 | -- | 2.63 | -- | 3.59 | 39.68 | 33.85 | 8.25 | 5.01 | -- | 3.43 | -- | 2.93 | 22.20 | 22.30 | 41.82 | 15.19 | 1.79 | -- |
| Albert David Ltd | 3.55bn | 662.42m | 6.77bn | 1.27k | 10.22 | -- | 9.21 | 1.91 | 116.07 | 116.07 | 621.75 | -- | -- | -- | -- | 2,791,696.00 | -- | 7.61 | -- | 10.17 | 64.33 | 60.21 | 18.67 | 8.47 | -- | 108.22 | -- | 16.18 | 8.95 | 3.40 | 2.60 | 21.82 | 6.81 | 10.35 |
| Valiant Laboratories Ltd | -100.00bn | -100.00bn | 6.88bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 60.35 | -- | 27.66 | -- | -- | -- |
| IND Swift Laboratories Ltd | 11.92bn | 431.95m | 6.99bn | 1.50k | 16.15 | -- | 7.46 | 0.5863 | 7.32 | 7.32 | 201.78 | -- | -- | -- | -- | 7,966,648.00 | -- | 0.5374 | -- | 0.6839 | 47.60 | 40.86 | 3.67 | 1.08 | -- | 2.27 | -- | 0.00 | 16.23 | 9.54 | 2,314.83 | 16.71 | -9.61 | -- |
| Nectar Lifesciences Ltd | 16.32bn | 80.79m | 7.68bn | 1.59k | 93.87 | -- | 11.14 | 0.4706 | 0.3649 | 0.3649 | 74.40 | -- | -- | -- | -- | 10,271,550.00 | -- | 0.0556 | -- | 0.1038 | 27.40 | 15.63 | 0.495 | 0.0707 | -- | 0.7366 | -- | 32.09 | -8.70 | -4.33 | -196.55 | -- | -1.95 | -- |
| Sakar Healthcare Ltd | 1.51bn | 124.73m | 7.79bn | 297.00 | 58.73 | -- | 26.68 | 5.16 | 6.10 | 6.10 | 73.58 | -- | -- | -- | -- | 5,082,286.00 | -- | 6.35 | -- | 7.59 | 46.18 | 44.28 | 8.26 | 10.84 | -- | 2.40 | -- | -- | 4.00 | 20.23 | -16.30 | 27.31 | 56.31 | -- |
| Panacea Biotec Ltd | 5.52bn | -119.17m | 8.45bn | 1.09k | -- | -- | 16.43 | 1.53 | -1.89 | -1.89 | 89.86 | -- | -- | -- | -- | 5,046,990.00 | -- | 10.52 | -- | 18.65 | 56.88 | 50.87 | -2.21 | 27.34 | -- | -- | -- | 0.00 | -30.44 | -5.06 | -103.08 | -- | 21.89 | -- |
| Bajaj Healthcare Ltd | 4.98bn | 212.66m | 8.77bn | 1.06k | 41.20 | -- | 17.89 | 1.76 | 7.71 | -18.22 | 180.50 | -- | -- | -- | -- | 4,684,510.00 | -- | 9.86 | -- | 17.42 | 42.26 | 26.47 | 4.27 | 8.57 | -- | 1.66 | -- | -- | -0.9704 | 15.53 | -39.73 | 23.16 | 60.82 | 31.95 |
| Jagsonpal Pharmaceuticals Ltd | 2.21bn | 245.16m | 8.82bn | 940.00 | 35.88 | -- | 33.58 | 4.00 | 9.30 | 9.30 | 83.51 | -- | -- | -- | -- | 2,347,522.00 | -- | 10.02 | -- | 12.51 | 54.09 | 58.47 | 11.11 | 8.03 | -- | 30.39 | -- | 36.24 | 8.79 | 13.33 | 41.72 | -- | -39.20 | 118.67 |
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 9.34bn | 38.00 | 99.19 | 35.95 | 104.00 | 20.74 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Vimta Labs Ltd | 3.20bn | 413.41m | 10.29bn | 1.37k | 25.28 | -- | 13.64 | 3.21 | 18.37 | 18.37 | 142.48 | -- | -- | -- | -- | 2,342,054.00 | -- | 10.50 | -- | 12.94 | 75.80 | 72.82 | 12.90 | 11.92 | -- | 28.50 | -- | 12.37 | 14.34 | 11.64 | 16.55 | 24.00 | 15.39 | 0.00 |
| Windlas Biotech Ltd | 6.00bn | 526.38m | 11.82bn | 1.05k | 22.57 | -- | 17.88 | 1.97 | 25.18 | 25.18 | 286.98 | -- | -- | -- | -- | 5,723,394.00 | -- | -- | -- | -- | 37.06 | -- | 8.77 | -- | -- | 59.55 | -- | -- | 10.12 | -- | 11.91 | -- | -- | -- |
| Lincoln Pharmaceuticals Ltd | 5.51bn | 872.70m | 11.83bn | 1.70k | 13.56 | -- | 12.12 | 2.15 | 43.57 | 43.57 | 274.88 | -- | -- | -- | -- | 3,238,331.00 | -- | 13.75 | -- | 16.82 | 54.00 | 50.74 | 15.85 | 14.11 | -- | 41.54 | -- | 3.94 | 8.09 | 7.13 | 5.11 | 16.06 | 7.60 | 0.00 |
| Holder | Shares | % Held |
|---|---|---|
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 118.00 | 0.00% |
